Xiaoqi Liu
Corporate Officer/Principal chez Trialspark, Inc.
Profil
Xiaoqi Liu is currently the Director & Business Development at Formation Bio Inc since 2023.
Prior to this, he worked as Director & Business Development at Halozyme Therapeutics, Inc. from 2021 to 2022 and as Director, Strategy & Corporate Development at Gelesis, Inc. from 2020 to 2021.
Liu completed his graduate degree at Northwestern University and his undergraduate degree at Beijing Normal University.
Postes actifs de Xiaoqi Liu
Sociétés | Poste | Début |
---|---|---|
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | Corporate Officer/Principal | 01/01/2023 |
Anciens postes connus de Xiaoqi Liu
Sociétés | Poste | Fin |
---|---|---|
HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2022 |
GELESIS INC | Corporate Officer/Principal | 01/12/2021 |
Formation de Xiaoqi Liu
Northwestern University | Graduate Degree |
Beijing Normal University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | Finance |
Gelesis, Inc.
Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |